Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
85.37
-1.10 (-1.27%)
At close: Apr 28, 2026, 4:00 PM EDT
85.01
-0.36 (-0.42%)
After-hours: Apr 28, 2026, 4:15 PM EDT
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Apogee Therapeutics stock have an average target of 109.67, with a low estimate of 82 and a high estimate of 160. The average target predicts an increase of 28.46% from the current stock price of 85.37.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Apogee Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Buy | 3 | 3 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $105 → $110 | Buy | Maintains | $105 → $110 | +28.85% | Mar 30, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $95 → $125 | Strong Buy | Maintains | $95 → $125 | +46.42% | Mar 24, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $89 → $130 | Strong Buy | Maintains | $89 → $130 | +52.28% | Mar 24, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $130 → $160 | Strong Buy | Maintains | $130 → $160 | +87.42% | Mar 24, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $137 | Strong Buy | Reiterates | $137 | +60.48% | Mar 23, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.85
from -4.22
EPS Next Year
-5.75
from -4.85
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.97 | -4.62 | ||||||
| Avg | -4.85 | -5.75 | ||||||
| Low | -5.55 | -9.40 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.